BMS & Medicines Patent Pool Collaborates Over HIV Drug “Atazanavir”
By 2016, there will be approx. 1 M HIV patients who will need second-line AIDS treatment as offered by Bristol-Myers Squibb’s HIV drug, “Atazanavir” (brand name Reyataz). Taking that in serious consideration, BMS has...